Cyclic tetrapeptide analogs
The present technology provides compounds of Formula I (or pharmaceutically acceptable salts and/or solvates thereof) that are useful in treating a CNS-related disorder such as schizophrenia, schizoaffective disorder, migraine, depression, pain, drug addiction, drug use, and/or drug seeking behavior. Also provided are compositions, medicaments, and methods including such compounds.
1. A compound that is
or a pharmaceutically acceptable salt and/or solvate thereof.
2. A composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.
3. A pharmaceutical composition comprising an effective amount of a compound of claim 1 and a pharmaceutically acceptable carrier, wherein the effective amount is effective for treating and/or inhibiting a CNS-related disorder in a subject.
4. The pharmaceutical composition of claim 3 , wherein the effective amount is effective for treating and/or inhibiting schizophrenia, schizoaffective disorder, migraine, depression, drug addiction, drug use, and/or drug seeking behavior in the subject.
5. The pharmaceutical composition of claim 3 , wherein the pharmaceutical composition is formulated for parenteral administration, intravenous administration, subcutaneous administration, and/or oral administration.
6. A method comprising administering a pharmaceutical composition of claim 3 to a subject suffering from a CNS-related disorder.
7. The method of claim 6 , wherein the subject is suffering from schizophrenia, schizoaffective disorder, migraine, depression, drug addiction, drug use, and/or drug seeking behavior.
8. The method of claim 6 , wherein administering comprises oral administration.
9. A method comprising administering an effective amount of a pharmaceutical composition of claim 3 to a subject suffering from pain.
10. The method of claim 9 , wherein administering comprises oral administration.
11. A method comprising contacting a kappa opioid receptor with a pharmaceutical composition of claim 3 wherein the contacting agonizes and/or antagonizes the kappa opioid receptor.
12. The method of claim 11 , wherein the contacting occurs in vivo.
13. The method of claim 11 , wherein the contacting occurs in vitro.
14. The method of claim 11 , wherein the method further comprises contacting a mu opioid receptor, wherein the contacting does not antagonize the mu opioid receptor.
15. The method of claim 11 , wherein the method further comprises contacting a delta opioid receptor, wherein the contacting does not antagonize the delta opioid receptor.
16. The method of claim 13 , wherein the method further comprises contacting a mu opioid receptor, wherein the contacting does not antagonize the mu opioid receptor.
17. The method of claim 13 , wherein the method further comprises contacting a delta opioid receptor, wherein the contacting does not antagonize the delta opioid receptor.